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Abstract
Arctigenin, a lignan-derived compound, is a constituent of the seeds of Arctium lappa. Arctigenin was previously shown to
inhibit osteoclastogenesis; however, this inhibitory mechanism has yet to be elucidated. Here, we showed that arctigenin
inhibited the action of nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1), a key transcription factor for
osteoclastogenesis. NFATc1 in osteoclast precursors was activated through two distinct pathways: the calcineurin-
dependent and osteoblastic cell-dependent pathways. Among the several lignan-derived compounds examined, arctigenin
most strongly inhibited receptor activator of nuclear factor kB ligand (RANKL)-induced osteoclast-like cell formation in
mouse bone marrow macrophage (BMM) cultures, in which the calcineurin-dependent NFATc1 pathway was activated.
Arctigenin suppressed neither the activation of nuclear factor kB and mitogen-activated protein kinases nor the up-
regulation of c-Fos expression in BMMs treated with RANKL. However, arctigenin suppressed RANKL-induced NFATc1
expression. Interestingly, the treatment of osteoclast-like cells with arctigenin converted NFATc1 into a lower molecular
weight species, which was translocated into the nucleus even in the absence of RANKL. Nevertheless, arctigenin as well as
cyclosporin A (CsA), a calcineurin inhibitor, suppressed the NFAT-luciferase reporter activity induced by ionomycin and
phorbol 12-myristate 13-acetate in BMMs. Chromatin immunoprecipitation analysis confirmed that arctigenin inhibited the
recruitment of NFATc1 to the promoter region of the NFATc1 target gene. Arctigenin, but not CsA suppressed osteoclast-
like cell formation in co-cultures of osteoblastic cells and bone marrow cells, in which the osteoblastic cell-dependent
NFATc1 pathway was activated. The forced expression of constitutively active NFATc1 rescued osteoclastogenesis in BMM
cultures treated with CsA, but not that treated with arctigenin. Arctigenin also suppressed the pit-forming activity of
osteoclast-like cells cultured on dentin slices. These results suggest that arctigenin induces a dominant negative species of
NFATc1, which inhibits osteoclast differentiation and function by suppressing both calcineurin-dependent and osteoblastic
cell-dependent NFATc1 pathways.
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Introduction
Arctigenin, a lignan-derived compound, is one of the constit-
uents of the seeds of Arctium lappa. Arctigenin is a biologically active
lignan with anti-tumor, anti-inflammatory, anti-oxidant, anti-
proliferative, and anti-diabetic activities. Arctigenin was shown to
block the activation of Akt signaling induced by glucose starvation
in pancreatic tumors [1,2]. Arctigenin also exhibited anti-
inflammatory properties against lipopolysaccharide in a macro-
phage cell line by suppressing inducible nitric oxide synthase
expression and mitogen-activated protein (MAP) kinase signals
[3,4]. Arctigenin was recently shown to inhibit osteoclast
formation in mouse bone marrow macrophage (BMM) cultures
[5]. However, the precise mechanism by which arctigenin inhibits
osteoclast development remains to be determined.
Osteoclasts are bone-resorbing multinucleated cells formed from
monocyte/macrophage-lineage precursors [6,7]. Osteoblastic cells
such as immature osteoblast-lineage cells, osteoblasts, and osteocytes
regulate the differentiation of osteoclast precursors into osteoclasts.
Osteoblastic cells express two cytokines that are responsible for
osteoclastogenesis: macrophage colony-stimulating factor (M-CSF,
also called colony-stimulating factor 1) and receptor activator of
nuclear factor kB ligand (RANKL) [8–12]. Osteoclast precursors
have been shown to express c-Fms (the receptor of M-CSF) and
RANK (the receptor of RANKL) and differentiate into osteoclasts
in the presence of M-CSF and RANKL [13,14]. Osteoblastic cells
also express osteoprotegerin (OPG), a decoy receptor of RANKL.
OPG inhibits osteoclast differentiation by suppressing the interac-
tion between RANKL and RANK. Osteoclasts also express RANK,
and the RANKL-RANK interaction was shown to induce the bone-
resorbing activity of osteoclasts [6,7].
A previous study showed that bone-resorption stimulating
factors such as 1a,25-dihydroxyvitamin D3 [1a,25(OH)2D3],
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parathyroid hormone, and prostaglandin E2 (PGE2) enhanced the
expression of RANKL in osteoblastic cells [7]. RANKL activates
RANK-mediated signaling, including MAP kinases, nuclear factor
kB (NF-kB), c-Fos, and nuclear factor of activated T-cells,
cytoplasmic 1 (NFATc1). These RANK-mediated signals induce
the expression of osteoclast-related genes such as tartrate-resistant
acid phosphatase (TRAP, coded by Acp5), cathepsin K (Ctsk),
osteoclast-associated receptor (Oscar), and Nfatc1 itself [15–17].
NFATc1 was identified as a key transcription factor for
osteoclastogenesis [15,18]. The Ca2+ oscillation/calcineurin-
dependent activation and amplification of NFATc1 in osteoclast
precursors are essential for their differentiation into osteoclasts.
RANKL induces Ca2+ oscillations in osteoclast precursors, and
these oscillations activate calcineurin, a Ca2+-dependent phospha-
tase. Activated calcineurin then dephosphorylates multiple serine
residues in the NFATc1 protein, which permits the nuclear
translocation of NFATc1. NFATc1 in the nucleus acts as a
transcription factor for genes specifically expressed in osteoclasts
such as Acp5, Ctsk, Oscar, and Nfatc1 itself. The calcineurin
inhibitors, cyclosporin A (CsA) and FK506, have been shown to
suppress RANKL-induced osteoclast formation in BMM cultures.
Osteoclastogenesis induced by RANKL also requires co-
stimulatory receptor signaling through adaptors containing im-
munoreceptor tyrosine-based activation motifs (ITAMs). ITAM-
containing proteins, such as DNAX-activating protein 12 (DAP12)
and Fc receptor common c chain (FcRc), facilitate the calcium-
mobilizing mechanism during osteoclastogenesis [19–22]. Thus,
RANK and ITAM signalings cooperated to induce calcium
oscillations, resulting in the activation of NFATc1. FcRc and
DAP12 are adaptor molecules that associate with immunoglobu-
lin-like receptors such as OSCAR, triggering receptor expressed
on myeloid cells 2 (TREM2), signal-regulatory protein b1
(SIRPb1) and paired immunoglobulin-like receptor A (PIR-A).
OSCAR and PIR-A use FcRc, while TREM2 and SIRPb1
associate with DAP12. Recently, Barrow et al. reported that
OSCAR bound to a specific motif of collagen and stimulated
osteoclastogenesis [23]. These results suggest that osteoblastic cells
express not only RANKL and M-CSF but also ligands for
immunoglobulin-like receptors.
Besides Ca2+/calcineurin-dependent signaling, the osteoblastic
cell-dependent pathway has also been shown to activate NFATc1
[24,25]. BMMs obtained from type 2 inositol-1,2,5-triphosphate
receptor (IP3R2) knockout mice exhibited neither RANKL-
induced Ca2+ oscillations nor RANKL-induced differentiation
into osteoclasts. However, IP3R2-deficient osteoclast precursors
could normally differentiate into osteoclasts when they were co-
cultured with osteoblastic cells. This Ca2+ oscillation-independent
osteoclastogenesis was shown to be insensitive to FK506 [24].
Kuroda et al. recently showed that Cot, a serine/threonine kinase,
was involved in the activation and amplification of NFATc1 in the
absence of Ca2+ oscillations. Cot in osteoclast precursors was
activated by cell-cell interactions with osteoblastic cells. Activated
Cot increased NFATc1 protein levels through phosphorylation-
dependent protein stabilization, thereby amplifying NFATc1 [25].
Cot likely phosphorylates residues of NFATc1 that differ from
those targeted by calcineurin-mediated dephosphorylation. Al-
though the osteoblastic cell-derived molecules that activate Cot in
osteoclast precursors is unknown, Cot-mediated NFATc1 stabili-
zation contributes to osteoclastogenesis in vivo. Mice doubly
deficient in DAP12 and FcRc exhibited severe osteopetrosis
owing to the lack of osteoclasts [22]. These results suggest that
both calcineurin-dependent and osteoblastic cell-dependent acti-
vations of NFATc1 are physiologically important in controlling
osteoclast differentiation in vivo.
The aim of this study was to elucidate the inhibitory mechanism
of arctigenin on the osteoclast differentiation and function.
Especially, we examined the intracellular signals including
NFATc1 in detail. Arctigenin converted NFATc1 into a lower
molecular species, which was translocated in the nucleus of
osteoclast-like cells even in the absence of RANKL. Arctigenin
inhibited osteoclast-like cell formation not only in BMM cultures,
but also in co-cultures of osteoblastic cells and bone marrow cells.
In addition, arctigenin suppressed the pit-forming activity of
osteoclast-like cells cultured on dentin. These results suggest that
arctigenin suppresses both calcineurin-dependent and osteoblastic
cell-dependent NFATc1 pathways through the generation of a
dominant species of NFATc1.
Materials and Methods
Reagents and animals
Arctigenin, arctiin, and secoisolariciresinol were purified from
Arctium lappa and single peaks were confirmed by high performance
liquid chromatography. The chemical structures of these com-
pounds were shown in Figure 1A. Human recombinant RANKL
was purchased from PeproTech (Rocky Hill, NJ). Human M-CSF
(Leukoprol) was obtained from Kyowa Hakko (Tokyo, Japan).
1a,25(OH)2D3 was from Wako Pure Chemical (Osaka, Japan).
CsA, PGE2, phorbol 12-myristate 13-acetate (PMA), and iono-
mycin were from Calbiochem-Sigma (St. Louis, MO). Antibodies
for p38, ERK, JNK, IkBa, AKT, and NF-kB p65, and antibodies
for phosphorylated forms of p38, ERK, JNK, IkBa, and AKT
were from Cell Signaling Technology (Danvers, MA). Antibodies
for NFATc1 (7A6), Lamin A/C, and b-actin were obtained from
Thermo (Rockford, IL), Santa Cruz (Dallas, TX), and Sigma,
respectively. Other chemicals used were of analytical grade.
Newborn and 6-week-old ddY mice were purchased from Japan
SLC (Shizuoka, Japan).
Ethics statement
All animal experiments in this study were approved by the
Institutional Animal Care and Use Committee of Matsumoto
Dental University. All steps were performed to limit suffering in all
animal experiments.
In vitro osteoclast-like cell differentiation
Mouse BMMs were prepared as previously described [26].
Briefly, mouse bone marrow cells were cultured for 16 h in a-
modified minimal essential medium (a-MEM) with 10% fetal
bovine serum (FBS) and 5000 U/mL M-CSF. Non-adherent cells
were then collected and used as BMMs. BMMs (36104 cells/well)
for osteoclast formation assay were cultured for 3 days in 96-well
culture plates in the presence of 5000 U/mL M-CSF and 100 ng/
mL RANKL together with increasing concentrations of lignan-
derived compounds or 0.1% dimethyl sulfoxide (DMSO, vehicle
control). Osteoblastic cells were obtained form newborn mouse
calvariae for the co-culture experiments. Bone marrow cells
(16105 cells/well) and calvarial osteoblastic cells (16104 cells/
well) were co-cultured for 6 days in a-MEM with 10% FBS in the
presence of 10 nM 1a,25(OH)2D3 together with or without test
compounds. After cultivation for the indicated periods, cells were
fixed and stained for TRAP. TRAP-positive multinucleated cells
containing more than three nuclei were counted as osteoclast-like
cells. The effects of lignan-derived compounds on the proliferation
of BMMs were also evaluated. BMMs (16103 cells/well) were
cultured with increasing concentrations of lignan-derived com-
pounds in 96-well culture plates. The cultures were subjected to
the cell viability Alamar Blue assay (Invitrogen, Carlsbad, CA).
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Pit formation assay and actin ring staining
Functionally active osteoclast-like cells were prepared using a
mouse co-culture system [27]. Bone marrow cells (16107 cells) and
osteoblastic cells (16106 cells) were co-cultured in collagen gel-
coated 10-cm plates in the presence of 10 nM 1a,25(OH)2D3 and
1 mM PGE2. After a co-culture for 7 days, the collagen-gel plate
was treated with collagenase. All cells recovered were suspended in
10 mL of a-MEM containing 10% FBS, and were used as
osteoclast-like cell preparations. Osteoclast-like cell preparations
were plated on dentin slices (a square piece of 4 mm, 0.75 mm in
thickness) in 96-well culture plates (0.2 mL/well) and incubated
for 1 h. Dentin slices were then transferred into 48-well culture
plates and cultured for an additional 48 h in a-MEM containing
10% FBS (0.5 mL/well) together with or without 1 mM arctigenin.
Dentin slices were then recovered, fixed, and stained for TRAP.
TRAP-positive cells were counted as osteoclast-like cells. Cells on
the slices were removed by cotton swabs and slices were further
stained with Mayer’s hematoxylin to detect resorbing pits.
Resorption pit areas were measured using ImageJ software. To
evaluate actin ring formation by osteoclast-like cells, cells on
dentin slices were fixed, permeabilized with 0.2% Triton X-100/
PBS, and stained with rhodamine-phalloidin (Invitrogen).
Western blot analysis
Cells were lysed in lysis buffer [20 mM Tris-HCl, pH7.6,
150 mM NaCl, 1 mM EDTA, 50 mM b-glycerophosphate, 1%
NP-40, and supplemented with 16 protease inhibitor cocktail
(Sigma)], sonicated, and supernatants were collected as total cell
lysates. Lysates (20 mg/lane) were electrophoresed on SDS-PAGE
gels, transferred to polyvinylidene difluoride membranes, and
subjected to immunoblotting using the ECL plus chemilumines-
cence detection system (GE Healthcare, Buckinghamshire, UK).
RNA isolation and quantitative RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen).
Reverse transcription was performed on 1 mg of RNA using
oligo(dT) primers and ReverTra Ace reverse transcriptase
(Toyobo Life Science, Osaka). cDNA was then amplified using
SYBR green Taq RT-PCR reagent (Takara Bio, Shiga, Japan)
and expression levels were quantified using the Opticon II real-
time PCR instrument (Bio-Rad, Hercules, CA). The primers used
for PCR were as follows; Gapdh: 59-TGT GTC CGT CGT GGA
TCT GA-39 (forward) and 59-TTG CTG TTG AAG TCG CAG
GAG-39 (reverse); Nfatc1: 59-TGG AGA AGC AGA GCA CAG
AC-39 (forward) and 59-GCG GAA AGG TGG TAT CTC AA-39
(reverse); c-Fos: 59-CCG AGC TGG TGC ATT ACA GAG A-39
(forward) and 59-TGG ATG CTT GCA AGT CCT TGA G-39
(reverse); Acp5: 59-TTG CGA CCA TTG TTA GCC ACA TA-39
(forward) and 59-TCA GAT CCA TAG TGA AAC CGC AAG-39
(reverse); Ctsk: 59-CAG CAG AAC GGA GGC ATT GA-39
(forward) and 59-CTT TGC CGT GGC GTT ATA CAT ACA-
39 (reverse); Oscar: 59-CGT GCT GAC TTC ACA CCA ACA-39
(forward) and 59-CAC AGC GCA GGC TTA CGT T-39
(reverse); Rankl: 59-CAT GTG CCA CTG AGA ACC TTG
AA-39 (forward) and 59 CAG GTC CCA GCG CAA TGT AAC-
39 (reverse); Opg: 59-CAT GAG GTT CCT GCA CAG CTT C-39
Figure 1. Effects of arctigenin on osteoclast-like cell formation and cell proliferation in BMM cultures. (A) Chemical structures of
arctigenin, arctiin, and secoisolariciresinol. (B) Effects of lignan-derived compounds on osteoclast-like cell formation in BMM cultures. BMMs were
cultured in 96-well culture plates in the presence of RANKL and M-CSF together with increasing concentrations of the lignan-derived compounds.
After cultivation for 3 days, cells were stained for TRAP. TRAP-positive cells appeared as dark red cells. TRAP-positive multinucleated cells containing
more than three nuclei were counted as osteoclast-like cells. (C) Effects of arctigenin on the proliferation of BMMs. BMMs were cultured in the
presence of M-CSF together with increasing concentrations of arctigenin. Cell proliferation was evaluated on days 0, 1, 2, and 3 using an Alamar Blue
assay. The results were expressed as means +/2 SD (n = 3). *, p,0.05.
doi:10.1371/journal.pone.0085878.g001
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(forward) and 59-ACA GCC CAG TGA CCA TTC CTA GTT
A-39 (reverse); IL-2: 59-GCT GTT GAT GGA CCT ACA GGA-
39 (forward) and 59-TTC AAT TCT GTG GCC TGC TT-39
(reverse); GM-CSF: 59-GCA TGT AGA GGC CAT CAA AGA-39
(forward) and 59 CGG GTC TGC ACA CAT GTT A-39
(reverse).
Nuclear extract preparation
Crude osteoclast-like cell preparations were cultured for 4 h on
24-well culture plates. Osteoblastic cells were then removed by
washing with 0.1% trypsin/EDTA solution. Purified osteoclast-
like cells were further cultured with M-CSF for 16 h. Cells were
then incubated for 20 min with 1 mM arctigenin, 1 mg/mL CsA,
or 0.1% DMSO (vehicle control) in the presence or absence of
100 ng/mL RANKL. Nuclear and cytoplasmic fractions were
prepared using a nuclear extraction kit (Active Motif, Carlsbad,
CA) and subjected to Western blot analysis.
Immunocytochemical localization of NFATc1
The localization of NFATc1 was immunocytochemically
examined [28]. Purified osteoclast-like cells on glass coverslips
were further cultured for 16 h in the presence of M-CSF, but in
the absence of RANKL. Osteoclast-like cells were then incubated
for 20 min with 1 mM arctigenin, 100 ng/mL RANKL, or 0.1%
DMSO (vehicle control). Cells were fixed with 4% paraformalde-
hyde, permeabilized with 0.2% Triton X-100/PBS, and blocked
with 2% BSA/PBS. An anti-NFATc1 antibody was added to cell
preparations, followed by incubation with biotinylated goat anti-
mouse IgG and fluorescein-conjugated streptavidin (Vector
Laboratories, Burlingame, CA). Nuclei were counterstained with
propidium iodide (PI).
Forced expression of NFATc1
BMMs were retrovirally transduced with NFATc1 cDNA. The
constitutively active (ca)-NFATc1 mutant with the alanine
substitution of twenty serine residues, which are typically
phosphorylated, was shown to be autonomously translocated into
the nucleus [29]. The pCX4pur-ca-NFATc1 (constitutively active),
pCX4pur-wt-NFATc1 (wild-type), or pCX4pur-GFP control
plasmid was transfected into the retrovirus packaging cell line
Plat-E [30]. BMMs were incubated for 2 days with virus-rich
supernatant in the presence of M-CSF and polybrene. Infected
BMMs were further cultured for 3 days with M-CSF and
RANKL. Nuclear and cytoplasmic fractions were prepared from
infected BMMs as described above, and subjected to Western blot
analysis.
Luciferase reporter assay
The luciferase reporter plasmid pNFAT-Luc, which contained
four copies of the NFAT binding site, 59-GGA GGA AAA ACT
GTT TCA TAC AGA AGG CGT-39, was used (Stratagene-
Agilent, La Jolla, CA). BMMs were transfected by electroporation
in serum-free solution with Nucleofector II (Amaxa Biosystems-
Lonza, Basel, Switzerland). Forty-eight hours after transfection,
cells were stimulated with 1 mM ionomycin and 20 nM PMA, in
the presence or absence of arctigenin and CsA. Cells were lysed
24 h after stimulation, and luciferase activity was measured with a
luciferase assay system (Promega, Madison, WI).
Chromatin immunoprecipitation (ChIP) assay
BMMs were stimulated with M-CSF and RANKL for 2 days
to form mononuclear pre-osteoclast-like cells. These cells were
further treated with 100 ng/mL RANKL in the presence or
absence of 1 mM arctigenin. Cells were crosslinked with 1%
formaldehyde 1 h after the treatment and a nuclear fraction was
extracted. The protein-chromatin complex was immunoprecip-
itated overnight at 4uC with the anti-NFATc1 antibody or
control IgG after shearing DNA by sonication. Fragmented
DNA were purified and amplified by PCR using primers specific
for the Oscar promoter [17]: 59-GAA CAC CAG AGG CTA
TGA CTG TTC-39 and 59-CCG TGG AGC TGA GGA AAA
GGT TG-39.
Cultures of osteoblastic cells
Osteoblastic cells were obtained from newborn mouse calvariae
as described [27]. Osteoblastic cells were cultured in a-MEM with
10% FBS. Osteoblastic cells were cultured in the presence or
absence of 10 nM 1a,25(OH)2D3 together with or without 1 mM
arctigenin for gene expression analysis. The expression of Rankl
and Opg mRNAs was analyzed after cultivation for 24 h by
quantitative RT-PCR. Osteoblastic cells were cultured in the
presence or absence of 1 mM arctigenin to stain for alkaline
phosphatase, a marker of osteoblasts. After cultivation for 6 days,
cells were fixed and stained for alkaline phosphatase. Osteoblastic
cells were cultured with increasing concentrations of arctigenin for
the cell growth assay. The cultures were then subjected to the cell
viability Alamar Blue assay (Invitrogen).
Statistical analysis
All data were expressed as the mean +/2 SD. Differences were
evaluated by Mann-Whitney’s U-test. P values less than 0.05
were considered to be significant. All experiments were indepen-
dently repeated at least three times and similar results were
obtained.
Results
Effect of lignan-derived compounds on osteoclast-like
cell formation
Arctigenin, arctiin, and secoisolariciresinol are major lignan-
derived compounds of Arctium lappa. We first compared the
inhibitory effects of these compounds on osteoclast-like cell
formation in mouse BMM cultures (Fig. 1 and Fig. S1). Mouse
BMMs were cultured in the presence of RANKL and M-CSF
together with increasing concentrations of these compounds.
Osteoclast-like cells formed within 3 days in control cultures.
Arctigenin and arctiin inhibited osteoclast-like cell formation in a
dose-dependent manner (Fig. 1B). Arctigenin showed stronger
inhibitory effects on osteoclast-like cell formation than that of
arctiin. Secoisolariciresinol failed to inhibit osteoclast-like cell
formation (Fig. S1). Thus, arctigenin showed the strongest
inhibitory effect on osteoclast-like cell formation among the three
lignans. We next examined the effects of arctigenin on the growth
of BMMs (Fig. 1C). Arctigenin had little effect on the growth of
BMMs, through 10 mM arctigenin slightly suppressed it on days 1
and 2. The treatment of BMMs with granulocyte-macrophage
colony-stimulating factor (GM-CSF) induced their differentiation
into dendritic cells. Arctigenin at 1 mM had no inhibitory effect on
the dendritic differentiation of BMMs (Fig. S2).These results
suggested that the inhibitory effect of arctigenin was specific for
osteoclast-like cell differentiation, and was not due to its action on
cell growth. Arctigenin at 1 mM inhibited osteoclast-like cell
formation more strongly than arctiin did. Therefore, arctigenin at
1 mM was used in further experiments.
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Effect of arctigenin on RANKL-induced signaling in
osteoclastogenesis
RANKL was previously shown to induce the transcription of
osteoclast-related genes such as Acp5, Ctsk, and Oscar by activating
NFATc1 [15]. The expression of Nfatc1 itself was also shown to be
up-regulated during osteoclastogenesis [31]. We examined the
effect of arctigenin on the expression of these osteoclast-related
genes in BMMs during osteoclastogenesis (Fig. 2A). Arctigenin
reduced the expression of Acp5, Ctsk, and Oscar at each time point.
The expression of the transcription factors, Nfatc1 and c-Fos, was
also up-regulated by the treatment with RANKL. The RANKL-
induced up-regulation of Nfatc1 expression, but not that of c-Fos,
was reduced by arctigenin throughout the experimental period.
We next examined the effect of arctigenin on RANKL-induced
signals in BMMs (Fig. 2B). RANKL has been shown to activate
NF-kB and MAP kinases, including p38 MAP kinase, ERK, and
JNK [32,33]. Western blot analysis revealed that these signals
were similarly activated by RANKL in BMMs in the presence and
absence of 1 mM arctigenin (Fig. 2B). A previous study showed
that Akt was one of the targets of arctigenin in tumor cells. The
phosphorylation of Akt in BMMs was up-regulated by RANKL,
and arctigenin had little effect on this phosphorylation (Fig. 2B).
These results suggested that arctigenin inhibited other pathways
involved in osteoclastogenesis, independent of MAP kinase, NF-
kB, and c-Fos signaling.
We next compared the inhibitory action of arctigenin with that
of the well-known inhibitors of osteoclastogenesis, CsA (a
calcineurin-NFAT inhibitor) and SB203580 (a p38 MAP kinase
inhibitor). Arctigenin, CsA, and SB203580 were added to BMM
cultures at different time points (Fig. 2C). Osteoclast-like cell
formation was inhibited by the addition of these agents during the
entire culture period (0-3 days). Arctigenin and CsA, but not
SB203580 inhibited osteoclast-like cell formation when they were
added 24 h after RANKL stimulation (1–3 days). Thus, signals
mediated by p38 MAP kinase appeared to be necessary for the
commitment of osteoclast precursors but not for the expression of
osteoclast-related markers in the committed cells [34]. The
inhibitory action of arctigenin on osteoclastogenesis was similar
to that of CsA. These results suggested that NFATc1 was a target
molecule of the arctigenin action in BMMs.
Effects of arctigenin on the transcriptional activity and
localization of NFATc1 in osteoclast-like cells
Osteoclast-like cells, which were formed in BMM cultures in the
presence of RANKL for 3 days, highly expressed NFATc1
(Fig. 2A). Using purified osteoclast-like cells obtained from co-
cultures performed in collagen gel-coated plates, we examined the
effect of arctigenin on the nuclear localization of NFATc1
(Fig. 3A). Osteoclast-like cells were cultured overnight in
RANKL-free medium. Cells were then treated with RANKL
together with or without arctigenin and CsA. Interestingly,
NFATc1 was translocated into the nuclei of osteoclast-like cells
in response to arctigenin even in the absence of RANKL (Fig. 3A,
lane 3). CsA did not show such activity, and inhibited the nuclear
translocation of NFATc1 induced by RANKL in osteoclast-like
cells (Fig. 3A, lanes 5 and 6). NF-kB p65 was also translocated into
the nuclei of osteoclast-like cells in response to RANKL (Fig. 3A,
lanes 2, 4, and 6). Neither arctigenin nor CsA inhibited the nuclear
translocation of NF-kB p65 (Fig. 3A, lanes 4 and 6). Immunocy-
tochemical analysis confirmed that arctigenin, even in the absence
of RANKL, promoted the nuclear localization of NFATc1 in
osteoclast-like cells (Fig. 3B). The nuclear localization of NFATc1
was also observed in osteoclast-like cells treated with RANKL.
Treating cells with ionomycin and PMA led to Ca2+ oscillations,
which induced the nuclear translocation of NFATc1 through the
activation of calcineurin. We then examined the effect of
arctigenin on the transcriptional activity of NFATc1 in BMMs
using a luciferase reporter assay, in which the luciferase gene was
driven by the NFAT-binding site (Fig. 3C). The treatment of
BMMs with ionomycin and PMA increased NFAT-driven
luciferase activity in BMM cultures. Arctigenin as well as CsA
suppressed the luciferase activity enhanced by ionomycin and
PMA. We then examined whether arctigenin inhibited the
recruitment of NFATc1 on the target gene promoters by using a
ChIP assay with the Oscar promoter (Fig. 3D). BMMs treated with
RANKL for 2 days were further cultured in the presence or
absence of arctigenin. RANKL stimulation induced the recruit-
ment of NFATc1 on the Oscar promoter (Fig. 3D, lane 3), whereas
arctigenin inhibited it (Fig. 3D, lane 4). These results indicated that
arctigenin inhibited NFATc1 transcriptional activity by suppress-
ing the recruitment of NFATc1 onto the target gene promoter,
and also that the mechanism for the inhibitory action of arctigenin
on osteoclast formation was different from that of CsA.
NFATc1 is commonly retained in the cytosol as a multi-
phosphorylated form. Ca2+ oscillations activate calcineurin, which
dephosphorylates NFATc1 [29,30]. We examined the effect of
arctigenin on the molecular mass of NFATc1 in osteoclast-like
cells (Fig. 3E). NFATc1 in osteoclasts was recognized as a broad
band around 90 kDa (Fig. 3E, lane 1). In contrast, NFATc1 in
osteoclast-like cells treated with arctigenin was detected as a major
band at 85 kDa (Fig. 3E, lane 3). NFATc1 in osteoclast-like cells
treated with CsA accumulated as a band at approximately
100 kDa, which may have been due to the hyper-phosphorylation
of NFATc1. It was reported that calf intestine alkaline phosphatase
(CIAP) dephosphorylated NFATc1 at more than 20 phosphory-
lated amino acid residues and produced lower molecular weight
species of NFATc1 in vitro [37]. NFATc1 in these cell lysates
shifted to approximately 85 kDa after being treated with CIAP
(Fig. 3E, lanes 2 and 4). These results suggest that arctigenin
converted NFATc1 into a lower molecular weight species.
Effect of arctigenin on osteoclastogenesis induced by the
forced expression of NFATc1
The constitutively active NFATc1 mutant (ca-NFATc1) was
shown to be autonomously translocated into the nucleus [37]. We
examined whether the forced expression of ca-NFATc1 could
rescue arctigenin-inhibited osteoclastogenesis (Fig. 4). BMMs were
retrovirally transduced with ca-NFATc1, wild-type (wt)-NFATc1,
and control GFP cDNA. The forced expression of ca-NFATc1,
but not wt-NFATc1 in BMMs rescued osteoclast-like cell
formation inhibited by CsA (Fig. 4A, lowest panels). In contrast,
ca-NFATc1 failed to rescue osteoclastogenesis inhibited by
arctigenin. Western blot analysis confirmed that ca-NFATc1 was
mainly located in the nucleus of BMMs, whereas wt-NFATc1 was
dominantly retained in the cytosol (Fig. 4B). These results suggest
that arctigenin did not inhibit the nuclear translocation of ca-
NFATc1, but reduced its transcriptional activity. It was also
reported that the survival of thymocytes was supported by
interleukin 7 (IL-7) through the phosphorylation of Tyr-371 in
NFATc1, and the forced expression of Y371F-NFATc1 mutant
enhanced the thymocyte survival [38]. Therefore, we examined
the effect of the Y371F mutant of NFATc1 on osteoclastogenesis
in the presence or absence of arctigenin. The overexpression of
Y371F-NFATc1 in BMMs neither induced osteoclastic differen-
tiation nor rescued osteoclastogenesis inhibited by arctigenin (Fig.
S3), suggesting that the phosphorylation status of Tyr-371 in
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Figure 2. Effects of arctigenin on RANKL-induced signaling in BMMs. (A) Effects of arctigenin on the expression of osteoclast-related genes.
BMMs were cultured in the presence of RANKL and M-CSF together with or without 1 mM arctigenin. After cultivation for the indicated periods, the
expression of Acp5, Ctsk, Oscar, Nfatc1, and c-Fos mRNAs was analyzed by quantitative RT-PCR. Expression levels were normalized to Gapdh and
expressed relative to day 0. Statistical analysis was performed between the control and arctigenin-treated values at indicated time points. (B) Effects
of arctigenin on RANKL-induced signals in BMMs. BMMs were pretreated for 10 min with 1 mM arctigenin and further treated with RANKL. Whole cell
lysates were harvested and analyzed by Western blotting with the indicated antibodies. (C) Effects of arctigenin, CsA, and SB203580 on osteoclast-like
cell formation in BMM cultures. BMMs were cultured for 3 days in the presence of RANKL and M-CSF. BMM cultures were also treated with 1 mM
arctigenin, 1 mg/mL CsA, or 1 mM SB203580 during days 0 – 3 and days 1 – 3. Cells were then fixed and stained for TRAP. TRAP-positive
multinucleated cells containing more than three nuclei were counted as osteoclast-like cells. The results were expressed as means +/2 SD (n = 3).
*, p,0.05.
doi:10.1371/journal.pone.0085878.g002
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NFATc1 is not involved in the inhibitory effect of arctigenin on
osteoclastogenesis.
Effect of arctigenin on osteoclastogenesis induced by the
osteoblastic cell-dependent NFATc1 pathway
NFATc1 has also been shown to be activated by the osteoblastic
cell-dependent pathway [24,25]. We compared the effect of
arctigenin on 1a,25(OH)2D3-induced osteoclast-like cell formation
in co-cultures of osteoblastic cells and bone marrow cells with that
of CsA (Fig. 5A). Arctigenin strongly inhibited osteoclast-like cell
formation in the co-culture, whereas CsA did not abrogate
osteoclastogenesis supported by osteoblastic cells. 1a,25(OH)2D3
increased Rankl expression and decreased Opg expression in
osteoblastic cells, both of which were not affected by arctigenin
(Fig. 5B). The appearance of alkaline phosphatase-positive
osteoblastic cells in osteoblastic cell cultures was not affected by
arctigenin (Fig. 5C). Arctigenin had no effect on the proliferation
of osteoblastic cells at the concentrations examined (Fig. 5D).
These results suggest that arctigenin directly acted on precursors of
osteoclast-like cells in the co-cultures, and inhibited their
differentiation into osteoclast-like cells by suppressing the osteo-
blastic cell-dependent NFATc1 pathway.
Effect of arctigenin on the pit-forming activity of
osteoclast-like cells
There is little conclusive evidence to show that NFATc1 plays
an essential role in osteoclast function because an NFATc1
deficiency induces osteopetrosis without osteoclasts. We examined
the effect of arctigenin on the pit-forming activity of osteoclast-like
cells (Fig. 6). Osteoclast-like cell preparations obtained from co-
cultures in collagen gel-coated plates were placed on dentin slices
and further cultured for 48 h in the presence of increasing
Figure 3. Effects of arctigenin on the nuclear translocation and activation of NFATc1. (A) Effects of arctigenin and CsA on the nuclear
translocation of NFATc1 and NF-kB in osteoclast-like cells. Purified osteoclast-like cells were cultured for 16 h in the absence of RANKL. Osteoclast-like
cells were then pre-treated for 20 min with or without 1 mM arctigenin or 1 mg/mL CsA, and then further incubated for 20 min with or without
RANKL. Nuclear fractions were analyzed by Western blotting with the antibodies indicated. (B) Immunohistochemical detection of NFATc1 in
osteoclast-like cells. Purified osteoclast-like cells were cultured on glass plates for 16 h in the absence of RANKL. Cells were then treated for 20 min
with or without 1 mM arctigenin or 100 ng/mL RANKL. Cells were fixed and stained for NFATc1 (green). Nuclei were counterstained with propidium
iodide (PI, red). Bar = 50 mm. (C) Effects of arctigenin and CsA on NFAT reporter activity. BMMs were transfected with the NFAT-luciferase construct.
Forty-eight hours later, cells were incubated for an additional 24 h with or without ionomycin and PMA. Some cultures were treated with 1 mM
arctigenin or 1 mg/mL CsA. The fluorescence of the lysates was measured by a luminometer. The results were expressed as means +/2 SD (n = 3).
*, p,0.05. (D) ChIP assay on the Oscar promoter. BMMs were cultured for 2 days in the presence of RANKL and M-CSF. Cells were then treated for 1 h
with or without 1 mM arctigenin. Chromatin complexes were immunoprecipitated with the anti-NFATc1 antibody or control IgG. Chromatin DNA
fragments were subjected to PCR for the Oscar promoter. (E) Western blotting of NFATc1 in osteoclast-like cells. Purified osteoclast-like cells were
treated for 10 min with or without 1 mM arctigenin or 1 mg/mL CsA. Cell lysates were then collected. Half of the lysates were treated for 30 min with
calf intestine alkaline phosphatase (CIAP). Samples were analyzed by Western blotting with the anti-NFATc1 antibody.
doi:10.1371/journal.pone.0085878.g003
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concentrations of arctigenin. The number of TRAP-positive cells
on dentin slices after cultivation for 48 h was not significantly
changed by the treatment with arctigenin (Fig. 6A), which
suggested that the survival of osteoclast-like cells supported by
osteoblastic cells was not affected by arctigenin. Cells were then
removed, and dentin slices were stained with Mayer’s hematoxylin
(Fig. 6B). Many resorption pits (purple areas) were formed on the
slices in control cultures. The pit-forming activity of osteoclast-like
cells was inhibited by arctigenin in a dose-dependent manner.
Osteoclast-like cells on bone form actin rings (corresponding to
sealing zones) to resorb bone. We examined the effect of arctigenin
on actin ring formation by osteoclast-like cells. Osteoclast-like cells
cultured on dentin slices formed actin rings even in the presence of
arctigenin (Fig. 6C). Thus, arctigenin suppressed the bone-
resorbing activity of osteoclast-like cells without affecting their
survival or cytoskeletal structures.
Discussion
We showed that arctigenin inhibited osteoclast-like cell differen-
tiation and function in a dose-dependent manner. Both the
differentiation and function of osteoclast-like cells were almost
completely inhibited by 1 mM arctigenin. Arctiin also inhibited
osteoclast-like cell differentiation, but a higher concentration was
needed to achieve the same effect as that of arctigenin. The
chemical structure of arctigenin is similar to that of arctiin, a
glucoside of arctigenin, but not to secoisolariciresinol. These results
suggest that the target molecule of arctigenin and arctiin is the same
in BMMs. Arctigenin has been shown to affect various biological
reactions in vitro. The minimum effective concentration of arctigenin
in most reactions was reported to be much higher than 1 mM [4,39–
42]. The differentiation of BMMs into dendritic cells was not
affected by arctigenin. These results suggest that the target molecule
of arctigenin is very specific for osteoclast lineage cells.
Kim et al. previously reported that arctigenin suppressed
activation of NF-kB, phosphorylation of ERK, and amplification
of NFATc1 in BMMs [5]. However, significant suppression of NF-
kB and ERK signals by arctigenin was not observed in our cultures.
Such a difference may be due to the different experimental
conditions employed. The arctigenin-induced suppression of
NFATc1 amplification was similarly observed in both Kim et al.’s
and our experiments. Several lines of evidence in our experiments
have indicated that the target molecule of arctigenin was NFATc1
in BMMs and osteoclast-like cells. First, arctigenin specifically
suppressed the RANKL-induced up-regulation of NFATc1 in
BMMs. Arctigenin had no inhibitory effect on the RANKL-induced
activation of NF-kB and MAP kinases or the expression of c-Fos.
Second, arctigenin as well as CsA could suppress the osteoclastic
differentiation of BMMs even when added at the late stage of the
culture. BMMs in the late stage of cultures are committed osteoclast
precursors, which already express high levels of NFATc1. Third,
similar to CsA, arctigenin suppressed the transcription activity of
NFATc1 in a luciferase reporter assay. However, the reappearance
of IkBa in BMMs treated with RANKL was not affected by
arctigenin (Fig. 2B). This suggests that arctigenin does not inhibit
the transcriptional activity of NF-kB. Fourth, arctigenin inhibited
the RANKL-induced transcriptional activity of NFATc1 on the
Oscar promoter. Fifth, arctigenin inhibited osteoclast-like cell
formation in co-cultures with osteoblastic cells, in which osteoblastic
cell-dependent NFATc1 signaling had been activated. In addition,
arctigenin completely suppressed the pit-forming activity of mature
osteoclast-like cells. Interestingly, these effects of arctigenin were
observed at a concentration as low as 1 mM. Taken together, these
results suggest that the target molecule of arctigenin is the same in
BMMs and mature osteoclast-like cells, and NFATc1 is the most
possible target of arctigenin in osteoclast-lineage cells (Fig. 6D).
Figure 4. Effect of arctigenin on osteoclast-like cell formation induced by the forced expression of NFATc1. (A) Osteoclast-like cell
formation in BMM cultures. BMMs were retrovirally transduced with constitutively active (ca)-NFATc1, wild-type (wt)-NFATc1, or control GFP genes,
and cultured for 2 days in the presence of M-CSF. Cells were further cultured in the presence of RANKL and M-CSF together with or without 1 mM
arctigenin or 1 mg/mL CsA. After cultivation for 3 days, cells were fixed and stained for TRAP. TRAP-positive multinucleated cells containing more than
three nuclei were counted as osteoclast-like cells. The results were expressed as means +/2 SD (n = 4). *, p,0.05. **, p,0.01. Bar = 50 mm. (B)
Subcellular distribution of NFATc1. Nuclear and cytosol fractions were prepared from BMMs transfected with or without ca-NFATc1 and wt-NFATc1
and analyzed by Western blotting with the anti-NFATc1 antibody.
doi:10.1371/journal.pone.0085878.g004
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How does arctigenin inhibit the action of NFATc1 in BMMs
and mature osteoclasts? Arctigenin induced the nuclear translo-
cation of NFATc1, but not that of NF-kB in osteoclast-like cells in
the absence of RANKL. The molecular weight of NFATc1 in
osteoclast-like cells was reduced to approximately 85 kDa by the
treatment with arctigenin, but not with CsA, which indicated that
arctigenin-induced modification of NFATc1. These results
suggested that arctigenin-treated NFATc1 acted as the domi-
nant-negative form of NFATc1. In support of this hypothesis, the
forced expression of a ca-NFATc1 mutant failed to rescue
arctigenin-inhibited osteoclastogenesis. The amount of force-
expressed ca-NFATc1 was much higher than that of endogenous
NFATc1 (Fig. 4B). This finding may also indicate that arctigenin
inactivate even the ca-NFATc1 mutant. In addition, arctigenin,
but not CsA strongly inhibited osteoclast-like cell formation in co-
cultures with osteoblastic cells. These results suggest that a
dominant-negative form of NFATc1 processed by arctigenin can
suppress both calcineurin-dependent and osteoblastic cell-depen-
dent NFATc1 signals.
Arctigenin induced the nuclear localization of 85 kDa NFATc1
in osteoclast-like cells even in the absence of RANKL. In order to
determine the mechanism of the production and nuclear
localization of 85 kDa NFATc1, we performed two additional
experiments. In one experiment, hemagglutinin (HA)-tagged ca-
NFATc1 (HA-ca-NFATc1) was expressed in BMMs, which were
treated with or without arctigenin. HA-ca-NFATc1 protein was
similarly detected as an 85 KDa protein in BMMs even in the
presence of arctigenin (Fig. S4). These results suggest that
arctigenin treatment does not cause the fragmentation of NFATc1.
NFATc1 also shifted to approximately 85 kDa after treatment
Figure 5. Effect of arctigenin on osteoclast-like cell formation in the co-culture with osteoblastic cells. (A) Effects of arctigenin and CsA
on osteoclast-like cell formation in the co-culture. Osteoblastic cells and bone marrow cells were co-cultured in the presence of 1a,25(OH)2D3
together with or without 1 mM arctigenin or 1 mg/mL CsA. After cultivation for 6 days, cells were fixed and stained for TRAP. TRAP-positive
multinucleated cells containing more than three nuclei were counted as osteoclast-like cells. Bar = 50 mm. (B) Effects of arctigenin on RANKL and OPG
expression in osteoblastic cells. Osteoblastic cells were cultured for 24 h in the presence or absence of 10 nM 1a,25(OH)2D3 together with or without
1 mM arctigenin. The expression of Rankl and Opg mRNAs was analyzed by quantitative RT-PCR. The expression level was normalized to Gapdh and
expressed relative to the vehicle control. (C) Alkaline phosphatase staining of osteoblastic cell cultures. Osteoblastic cells were cultured for 6 days in
the presence or absence of 1 mM arctigenin. Cells were then fixed and stained for alkaline phosphatase. Alkaline phosphatase-positive cells appeared
as blue cells. Bar = 50 mm. (D) Effects of arctigenin on the proliferation of osteoblastic cells. Osteoblastic cells were cultured with increasing
concentrations of arctigenin. Cell proliferation was evaluated on days 0, 1, and 2 using an Alamar Blue assay. The results were expressed as means
+/2 SD (n = 3). p,0.05.
doi:10.1371/journal.pone.0085878.g005
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with CIAP (Fig. 3E). Therefore, it is possible that arctigenin
enhances dephosphorylation of NFATc1. We then examined
effects of phosphatase inhibitors such as 3,4-dephostatin [protein
tyrosine phosphatase (PTP) inhibitor], NSC87877 [SH2 domain-
containing inositol phosphatase (SHIP) 1/2 and PTP1B inhibitor],
okadaic acid (protein phosphatase 2A inhibitor), and sodium
stibogluconate (SHIP1 inhibitor) on the arctigenin-induced
conversion of NFATc1. However, those phosphatase inhibitors
failed to suppress the arctigenin-induced production of 85 kDa
NFATc1 (Fig. S5). Thus, the mechanism of the arctigenin-induced
production and nuclear localization of 85 kDa NFATc1 and the
structure-function relationship of NFATc1 are still unknown. The
mass spectrometry analysis on the NFATc1 protein to determine
the phosphorylation status will elucidate the mechanism of
arctigenin-induced modifications of NFATc1.
Interleukin 2 (IL-2) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) were reported to be the target genes
of NFATc1 in T cells [35,36,43]. Our preliminary experiments
showed that neither the expression of IL-2 nor that of GM-CSF in
splenic T cells was inhibited by arctigenin, while CsA suppressed
the expression of both genes (Fig. S6). Unlike osteoclasts, T cells
have been shown to express NFATc2 and NFATc3 as well as
NFATc1 [35,44]. Therefore, other NFAT family members may
compensate for the loss of NFATc1 activity in T cells treated with
arctigenin. The differentiation of BMMs into osteoclasts is shown
to be tightly regulated by NFATc1. These results suggest that the
Figure 6. Effect of arctigenin on osteoclast-like cell function. (A) Effects of arctigenin on the pit-forming activity of osteoclast-like cells
cultured on dentin slices. Osteoclast-like cell preparations were cultured on dentin slices in the presence or absence of 1 mM arctigenin. After
cultivation for 48 h, cells on the slices were fixed and stained for TRAP. TRAP-positive cells were counted as osteoclast-like cells. Cells were then
removed from dentin slices, and slices were stained with Mayer’s hematoxylin to visualize resorption pits. Resorption pit areas were measured using
ImageJ software. The results were expressed as means +/2 SD (n = 6). *, p,0.01. Bar = 50 mm. (B) Effect of arctigenin on actin ring formation by
osteoclast-like cells. Osteoclast-like cell preparations were cultured on dentin slices in the presence or absence of 1 mM arctigenin. After cultivation for
24 h, cells on the slices were fixed and stained with Rhodamine-phalloidin. Bar = 50 mm. (C) A hypothetical model for the action of arctigenin on the
differentiation and function of osteoclasts. Arctigenin inhibited RANKL-induced osteoclast-like cell formation in BMM cultures, in which the Ca2+/
calcineurin-dependent NFATc1 pathway was activated. Arctigenin also inhibited osteoclast-like cell formation in co-cultures with osteoblastic cells, in
which the osteoblastic cell-dependent NFATc1 pathway was activated. The pit-forming activity of osteoclast-like cells was also inhibited by arctigenin.
Arctigenin induced a lower molecular weight species of NFATc1, which may act as the dominant negative inhibitor of NFATc1.
doi:10.1371/journal.pone.0085878.g006
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inhibitory action of arctigenin on NFATc1 is specific for osteoclast
lineage cells. The calcinurin-dependent activation of NFATc1 was
shown to be necessary for the survival of thymocytes treated with
IL-7 [38]. Treatment of thymocytes with IL-7 induced the
phosphorylation of Tyr-371 in NFATc1, and the expression of
Y371F-NFATc1 enhanced the survival of thymocytes. However,
the expression of Y371F-NFATc1 in BMMs failed to rescue
arctigenin-induced inhibition of osteoclastogenesis (Fig. S3). These
results suggest that the action of arctigenin on NFATc1 signals is
regulated differently in osteoclast lineage cells and thymocytes.
Although NFATc1 signaling was previously proposed to be
involved in the bone-resorbing activity of osteoclasts, conclusive
evidence has not yet confirmed this. The genetic deletion of
NFATc1 in the osteoclast lineage cells resulted in a deficiency in
osteoclasts [15]. Therefore, difficulties are associated with investi-
gating the precise role of NFATc1 in the bone-resorbing activity of
osteoclasts. Komarova et al. demonstrated that local acidification
enhanced the bone-resorbing activity of osteoclasts through the
Ca2+/calcineurin-dependent NFATc1 pathway [45]. Treating
osteoclast-like cells with RANKL induced the nuclear translocation
of NFATc1 and their pit-forming activity. These results suggest that
NFATc1 is also involved in the activation of osteoclast-like cells. We
showed that arctigenin inhibited the pit-forming activity of
osteoclast-like cells cultured on dentin slices. This inhibitory effect
of arctigenin was observed at a concentration as low as 1 mM.
Interestingly, arctigenin showed no inhibitory effects on actin ring
formation or the survival of osteoclast-like cells. Calcitonin and
bisphosphonates, well-known inhibitors of osteoclast function, were
shown to disrupt actin rings in osteoclast-like cells [7]. These results
suggest that NFATc1 signals are involved in the bone-resorbing
activity of osteoclasts without affecting the survival or cytoskeletal
structure of osteoclasts (Fig. 6D).
In conclusion, arctigenin inhibited osteoclast-like cell formation
in BMM cultures and co-cultures with osteoblastic cells by
suppressing NFATc1 signals. Arctigenin appeared to induce the
dominant negative species of NFATc1. Thus, arctigenin promises
to be a useful agent for investigating the role of NFATc1 in
osteoclastic bone resorption. Further experiments will elucidate
the molecular mechanism for the inhibitory action of arctigenin on
the differentiation and function of osteoclasts.
Supporting Information
Figure S1 Effect of secoisolariciresinol on osteoclast-
like cell formation. The chemical structure of secoisolaricir-
esinol was shown. BMMs were cultured in 96-well culture plates in
the presence of RANKL and M-CSF together with increasing
concentrations of secoisolariciresinol. After cultivation for 3 days,
cells were stained for TRAP. TRAP-positive cells appeared as dark
red cells. TRAP-positive multinucleated cells containing more
than three nuclei were counted as osteoclast-like cells.
(TIF)
Figure S2 Effect of arctigenin on the differentiation of
dendritic cells. BMMs (1.56105 cells) were cultured for 1 week
in 60-mm dishes in the presence of 20 ng/mL GM-CSF with or
without 1 mM arctigenin. Cells were analyzed for the expression of
CD11c and CD86 by fluorescence-activated cell scanning. The
numbers in the top right corners indicate the percentages of
CD11c/CD86 double positive cells as differentiated dendritic cells.
Experiments were performed four times, and representative data
are shown.
(TIF)
Figure S3 Effect of arctigenin on osteoclast-like cell
formation induced by the forced expression of an Y371F-
NFATc1 mutant. BMMs (36104 cells) were retrovirally
transduced with Y371F-NFATc1 or control GFP, and cultured
for 2 days in the presence of 5000 U/mL M-CSF in 96-well
culture plates. Cells were further cultured in the presence of
100 ng/mL RANKL and/or 5000 U/mL M-CSF together with
or without 1 mM arctigenin. After cultivation for 3 days, cells
were fixed and stained for TRAP. TRAP-positive multinucleated
cells containing more than three nuclei were counted as
osteoclast-like cells. The results were expressed as means +/2
SD (n = 4).
(TIF)
Figure S4 Effect of arctigenin on processing NFATc1.
BMMs (36104 cells) were retrovirally transduced with a
hemagglutinin (HA)-tagged ca-NFATc1 cDNA, and cultured for
2 days in the presence of 5000 U/mL M-CSF in 96-well culture
plates. Cells were further cultured in the presence of 100 ng/mL
RANKL and 5000 U/mL M-CSF together with or without 1 mM
arctigenin. After cultivation for 2 days, total cell lysates were
analyzed by Western blotting analysis using an anti-HA antibody
or an anti-b-actin antibody.
(TIF)
Figure S5 Effect of phosphatase inhibitors on the
conversion of lower molecular species of NFATc1
induced by arctigenin. Purified osteoclast-like cells (2000 cells)
were cultured in 24-well culture plates in the presence or absence
of 10 mM 3,4-dephostatin [protein tyrosine phosphatase (PTP)
inhibitor], 10 mM NSC87877 [SH2 domain-containing inositol
phosphatase (SHIP)1/2 and PTP1B inhibitor], 0.5 mM okadaic
acid (protein phosphatase 2A inhibitor), or 100 mM sodium
stibogluconate (SHIP1 inhibitor) together with or without 1 mM
arctigenin. After cultivation for 10 min, whole cell lysates were
harvested and analyzed by Western blotting using an anti-
NFATc1 antibody.
(TIF)
Figure S6 Effect of arctigenin on the expression of T
cell-related genes. Mouse splenocytes (26106 cells) were
activated for 4 h in the presence of 1 mM ionomycin and 20 nM
PMA in 24-well culture plates. Cells were further cultured with or
without 1 mM arctigenin and 1 mg/mL CsA. After cultivation for
2 h, IL-2 and GM-CSF mRNA levels were analyzed by
quantitative RT-PCR. Expression levels were normalized to Gapdh
and the values were relative to unstimulated controls. The results
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